PURPOSE: Therapy for patients with chronic graft-versus-host disease (cGVHD) is based on prolonged immunosuppression with corticosteroids. There is no standard therapy for patients whose cGVHD does not resolve with corticosteroid treatment. Pentostatin, a potent inhibitor of adenosine deaminase, has activity in acute GVHD. We examined the toxicity and efficacy of pentostatin in a prospective phase II trial in corticosteroid-refractory cGVHD. PATIENTS AND METHODS: Patients of any age were eligible. Patients received pentostatin 4 mg/m2 intravenously every 2 weeks for 12 doses, and continued therapy as long as benefit was documented. Corticosteroid taper was begun after three doses of pentostatin. Responses were graded in real time in the skin, mouth, and liver using objective response criteria. RESULTS: Fifty-eight heavily pretreated (median, four prior regimens) patients (median age, 33 years) were enrolled. Results are shown as an intent-to-treat analysis. Of the 58 patients, a total of 32 (55%; 95% CI, 42% to 68%) had an objective response, as evaluated by use of a new grading scale. Infection was the most significant toxicity, with 11 grade 3 to 4 infectious events. The survival at 1 and 2 years was 78% (95% CI, 64% to 86%) and 70% (95% CI, 57% to 80%), with cGVHD with/without infection accounting for the majority of deaths. CONCLUSION: Pentostatin has immunosuppressive effects that are currently being explored further for treatment of cGVHD.
PURPOSE: Therapy for patients with chronic graft-versus-host disease (cGVHD) is based on prolonged immunosuppression with corticosteroids. There is no standard therapy for patients whose cGVHD does not resolve with corticosteroid treatment. Pentostatin, a potent inhibitor of adenosine deaminase, has activity in acute GVHD. We examined the toxicity and efficacy of pentostatin in a prospective phase II trial in corticosteroid-refractory cGVHD. PATIENTS AND METHODS: Patients of any age were eligible. Patients received pentostatin 4 mg/m2 intravenously every 2 weeks for 12 doses, and continued therapy as long as benefit was documented. Corticosteroid taper was begun after three doses of pentostatin. Responses were graded in real time in the skin, mouth, and liver using objective response criteria. RESULTS: Fifty-eight heavily pretreated (median, four prior regimens) patients (median age, 33 years) were enrolled. Results are shown as an intent-to-treat analysis. Of the 58 patients, a total of 32 (55%; 95% CI, 42% to 68%) had an objective response, as evaluated by use of a new grading scale. Infection was the most significant toxicity, with 11 grade 3 to 4 infectious events. The survival at 1 and 2 years was 78% (95% CI, 64% to 86%) and 70% (95% CI, 57% to 80%), with cGVHD with/without infection accounting for the majority of deaths. CONCLUSION:Pentostatin has immunosuppressive effects that are currently being explored further for treatment of cGVHD.
Authors: David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers Journal: Blood Date: 2012-07-06 Impact factor: 22.113
Authors: Linda M Griffith; Steven Z Pavletic; Stephanie J Lee; Paul J Martin; Kirk R Schultz; Georgia B Vogelsang Journal: Biol Blood Marrow Transplant Date: 2008-04 Impact factor: 5.742
Authors: Yoshihiro Inamoto; Joseph Pidala; Xiaoyu Chai; Brenda F Kurland; Daniel Weisdorf; Mary E D Flowers; Jeanne Palmer; Sally Arai; David Jacobsohn; Corey Cutler; Madan Jagasia; Jenna D Goldberg; Paul J Martin; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee; Paul A Carpenter Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Sally Arai; Joseph Pidala; Iskra Pusic; Xiaoyu Chai; Samantha Jaglowski; Nandita Khera; Jeanne Palmer; George L Chen; Madan H Jagasia; Sebastian A Mayer; William A Wood; Michael Green; Teresa S Hyun; Yoshihiro Inamoto; Barry E Storer; David B Miklos; Howard M Shulman; Paul J Martin; Stefanie Sarantopoulos; Stephanie J Lee; Mary E D Flowers Journal: Clin Cancer Res Date: 2015-09-16 Impact factor: 12.531
Authors: Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin Journal: Blood Date: 2013-01-15 Impact factor: 22.113
Authors: N Treister; X Chai; B Kurland; S Pavletic; D Weisdorf; J Pidala; J Palmer; P Martin; Y Inamoto; M Arora; M Flowers; D Jacobsohn; M Jagasia; S Arai; S J Lee; C Cutler Journal: Bone Marrow Transplant Date: 2013-01-28 Impact factor: 5.483